Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Decreases By 35.7%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBGet Free Report) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totalling 900 shares, a drop of 35.7% from the August 15th total of 1,400 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,200 shares, the days-to-cover ratio is presently 0.1 days.

Anebulo Pharmaceuticals Price Performance

NASDAQ:ANEB opened at $3.21 on Friday. The stock’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $2.61. Anebulo Pharmaceuticals has a twelve month low of $1.77 and a twelve month high of $4.05.

Anebulo Pharmaceuticals Company Profile

(Get Free Report)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Featured Articles

Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with's FREE daily email newsletter.